Both anti-MDA5+ DM patients and SARS-CoV-2-infected individuals are predisposed to developing concurrent ILD, particularly RP-ILD, which can lead to acute respiratory distress syndrome (ARDS) and mortality (19). Here, IFIH1 is linked to dermatomyositis.